Binding model for the interaction of anticancer arylsulfonamides with the p300 transcription cofactor

ACS Medicinal Chemistry Letters

Volumn 3, Issue 8, 2012, Pages 620-625

  Shi, Qi ^a   Yin, Shaoman ^b   Kaluz, Stefan ^a,b   Ni, Nanting ^c   Devi, Narra Sarojini ^b   Mun, Jiyoung ^a   Wang, Danzhu ^c   Damera, Krishna ^c   Chen, Weixuan ^c   Burroughs, Sarah ^c   Mooring, Suazette Reid ^c   Goodman, Mark M ^a,b   Van Meir, Erwin G ^a,b   Wang, Binghe ^c   Snyder, James P ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

binding model; HIF arylsulfonamide inhibitors; hypoxia; KCN1; p300; QSAR; solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P300; SULFONAMIDE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; IC 50; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE PLASMON RESONANCE;

EID: 84864921949     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300042k     Document Type: Article

References (34)

1. Brat, D. J.; Kaur, B.; Van Meir, E. G. Genetic modulation of hypoxia-induced gene expression and vascular proliferation: relevance to brain tumors Front. Biosci. 2002, 8, d100-d116
2. Lara, P. C.; Lloret, M; Clavo, B.; Apolinario, R. M.; Henríquez-Hernández, L. A.; Bordón, E.; Fontes, F.; Rey, A. Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression Radiat. Oncol. 2009, 4, 29
3. Belozerov, V.; Van Meir, E. G. Inhibitors of Hypoxia Inducible Factor-1 signaling Curr. Opin. Invest. Drugs 2006, 7, 1067-1076 (Pubitemid 44941751)
4. Kaur, B.; Tan, C.; Brat, D. J.; Van Meir, E. G. Genetic and hypoxic regulation of angiogenesis in gliomas J. Neuro-Oncol 2004, 70, 229-243 (Pubitemid 39545734)
5. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine Cell 2012, 148, 399-408
6. Arany, Z.; Huang, L. E.; Eckner, R.; Bhattacharya, S.; Jiang, C.; Goldberg, M. A.; Bunn, H. F.; Livingston, D. M. An essential role for p300/CBP in the cellular response to hypoxia Proc. Natl. Acad. Sci. 1996, 93, 12969-12973 (Pubitemid 26382753)
7. Bos, R.; van der Groep, P.; Greijer, A. E.; Shvarts, A.; Meijer, S.; Pinedo, H. M.; Semenza, G. L.; van Diest, P. J.; Van der Wall, E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma Cancer 2003, 97, 1573-1581 (Pubitemid 36297788)
8. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res. 1999, 59, 5830-5835
9. Mun, J.; Jabbar, A. A.; Devi, N. S.; Yin, S.; Wang, Y.; Tan, C.; Culver, D.; Snyder, J. P.; Van Meir, E. G.; Goodman, M. M. Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl] heteroarylsulfonamides, novel small molecule Hypoxia Inducible Factor-1 (HIF-1) pathway inhibitors and anti-cancer agents J. Med. Chem. 2012, in press
10. Kaur, B.; Khwaja, F. W.; Severson, E. A.; Matheny, S. L.; Brat, D. J.; Van Meir, E. G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis Neuro. Oncol. 2005, 7, 134-153 (Pubitemid 40590514)
11. Belozerov, V; Van Meir, E. G. Hypoxia Inducible factor-1: A novel target for cancer therapy Anti-Cancer Drugs 2005, 16, 901-909 (Pubitemid 41416080)
12. Narita, T.; Yin, S.; Gelin, C. F.; Moreno, C. S.; Yepes, M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small molecule HIF-1a translation inhibitor Clin. Cancer Res. 2009, 15, 6128-6136
13. Kim, H.-S.; Peng, G.-Y.; Hicks, J. M.; Weiss, H. L.; Van Meir, E. G.; Brenner, M. K.; Yotnda, P. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment Mol. Ther. 2008, 16, 599-606 (Pubitemid 351315001)
14. Post, D. E.; Sandberg, E. M.; Devi, S. N.; Brat, D. J.; Xu, Z.; Tighiouart, M.; Van Meir, E. G. Targeted cancer-gene therapy using a HIF-dependent oncolytic adenovirus armed with interleukin-4 Cancer Res. 2007, 67, 6872-6881 (Pubitemid 47105534)
15. Post, D. E.; Devi, N. S.; Li, Z.; Brat, D. J.; Kaur, B.; Nicholson, A.; Olson, J. J.; Zhang, Z.; Van Meir, E. G. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors Clin. Cancer Res. 2004, 10, 8603-8612 (Pubitemid 40053428)
16. Tan, C.; de Noronha, R. G.; Devi, N. S.; Jabbar, A. A.; Kaluz, S.; Liu, Y.; Mooring, S. R.; Nicolaou, K. C.; Wang, B.; Van Meir, E. G. Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 5528-5532
17. Reid-Mooring, S.; Jin, H.; Devi, N. S.; Jabbar, A. A.; Kaluz, S.; Liu, Y.; Van Meir, E. G.; Wang, B. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway J. Med. Chem. 2011, 54, 8471-8489
18. Mun, J.; Jabbar, A. A.; Devi, N. S; Liu, Y.; Van Meir, E. G.; Goodman, M. M. Structure-activity relationship of 2,2-dimethyl-2 H -chromene based arylsulfonamide analogs of 3,4-dimethoxy- N -[(2,2-dimethyl-2 H -chromen-6-yl)methyl]- N -phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent Bioorg. Med. Chem. 2012, 20, 4590-4597
19. Wang, W.; Ao, L.; Rayburn, E. R.; Xu, H.; Zhang, X.; Zhang, X.; Wang, M. H.; Wang, H.; Van Meir, E. G.; Zhang, R. KCN1, a novel synthetic sulfonamide anticancer agent: In vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. Submitted for publication.
20. Zhang, Q.; Kaluz, S.; Yang, H.; Van Meir, E. G.; Grossniklaus, H. E. Efficacy of the novel small molecule HIF pathway inhibitor KCN1 in the control of micrometastases in experimental ocular melanoma. Manuscript in preparation.
21. Yin, S.; Kaluz, S.; Devi, S. N.; Jabbar, A. A.;; de Norhona, R.; Wang, W.; Mun, J.; Boreddy, P. R.; Abbruscato, T.; Zhang, R.; Goodman, M. M.; Nicolaou, K. C.;; Van Meir, E. G. Arylsulfonamide KCN1 inhibits in vivo glioma growth and blocks HIF signaling. Submitted for publication.
22. De Guzman, R. N.; Wojciak, J. M.; Martinez-Yamout, M. A.; Dyson, H. J.; Wright, P. E. CBP/p300 TAZ1 Domain Forms a Structured Scaffold for Ligand Binding Biochemistry 2005, 44, 490-497 (Pubitemid 40105479)
23. Homola, J.; Yeea, S. S.; Gauglitzb, G. Surface plasmon resonance sensors: Review Sens. Actuators, B 1999, 54, 3-15
24. Pattnaik, P. Surface plasmon resonance: applications in understanding receptor-ligand interaction Appl. Biochem. Biotechnol. 2005, 126, 79-92 (Pubitemid 41206948)
25. Navratilova, I.; Hopkins, A. L. Emerging role of surface plasmon resonance in fragment-based drug discovery Future Med. Chem. 2011, 3, 1809-1820
26. de Mol, N. J. Surface plasmon resonance for proteomics Methods Mol. Biol. 2012, 800, 33-53
27. Freedman, S. J.; Sun, Z. Y.; Poy, F.; Kung, A. L.; Livingston, D. M.; Wagner, G.; Eck, M. J. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha Proc. Natl. Acad. Sci. 2002, 99, 5367-5372 (Pubitemid 34411554)
28. Glide, version 5.5; Schrödinger, LLC: New York, NY, 2009.
29. Prime, version 2.1; Schrödinger, LLC: New York, NY, 2009.
30. Dames, S. A.; Martinez-Yamout, M.; De Guzman, R. N.; Dyson, H. J.; Wright, P. E. Structural basis for HIF-1α/CBP recognition in the cellular hypoxic response Proc. Natl. Acad. Sci. 2002, 99, 5271-5276 (Pubitemid 34411538)
31. Gu, J.; Milligan, J.; Huang, L. E. Molecular Mechanism of Hypoxia-inducible Factor 1α-p300 Interaction J. Biol. Chem. 2001, 276, 3550-3554
32. http://en.wikipedia.org/wiki/Receiver-operating-characteristic; accessed 5/25/2012.
33. Tan, C.; de Noronha, R. G.; Roecker, A. J.; Pyrzynska, B.; Khwaja, F.; Zhang, Z.; Zhang, H.; Teng, Q.; Nicholson, A. C.; Giannakakou, P.; Zhou, W.; Olson, J. J.; Pereira, M. M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small molecule inhibitor of the hypoxia-inducible factor-1 (HIF-1) pathway Cancer Res. 2005, 65, 605-612
34. Kaluz, S.; Kaluzová, M.; Stanbridge, E. J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain Mol. Cell. Biol. 2006, 15, 5895-5907 (Pubitemid 44134343)